Business
Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product Commercialization
This milestone marks a pivotal point in Avalon's pipeline, now allowing the company to enter its next phase of commercializing clinical-grade exosome products
About this update from Avalon Globocare Corp.
[{"type":"text","content":"This milestone marks a pivotal point in Avalon's pipeline, now allowing the company to enter its next phase of commercializing clinical-grade exosome products\n FREEHOLD, New Jersey, June 10, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has achieved a major milestone in bio-production standardization of clinical-grade stem cell derived exosomes. The standardized procedure was a direct result of the previously announced co-development program at Weill Cornell Medicine with Yen-Michael Hsu, M.D., Ph.D. as principal investigator. The process has been co-developed and operated within Weill Cornell's cGMP-certified cell therapy facility jointly accredited under Foundation of Accreditation for Cellular Therapy (FACT), American Association of Blood Banking (AABB), College of American Pathologists (CAP), as well as Clinical Laboratory Improvement Amendment (CLIA).\nAvalon will hold a press conference to announce the launch of its exosome product commercialization plan, including a series of over-the-counter skincare and wound-healing products with Avalon's Clinical-grade Tissue-specific EXosomes as additives (ACTEX), on June 15, 2019 during the 2nd International Aesthetic Industry Conference in Chengdu, China -- the largest conference of its kind in Asia. In addition to product commercialization, this standardization of clinical-grade stem cell derived exosomes will lead to parallel development of Avalon's clinical programs, including AVA-202 and AVA-203, for angiogenic/orthopedic regeneration as well as treatment of fibrotic diseases. \n\"We are pleased to complete such a significant developmental milestone of our exosome program,\" stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare and Co-CEO of its subsidiary GenExosome Technologies. \"As a result, we look forward to an accelerated pathway of our exosome-based clinical programs for regenerative therapeutics as well as exosome product commercialization,\" added Dr. Jin.\nAbout Avalon GloboCare Corp.\nAvalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate a...